Ganitumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF-1R |
| Clinical data | |
| Identifiers | |
905703-97-1  | |
| None | |
| UNII |
CK1441RCZ8  |
| Chemical data | |
| Formula | C6472H10028N1728O2020S42 |
| 145.7 kDa | |
| (what is this?) (verify) | |
Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1]
Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[2][3]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American Medical Association.
- ↑ "Amgen Pulls Cancer Drug". 10 Aug 2012.
- ↑ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012.